The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies
Authors:
- 14 December 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 20 (5) , 551-566
Abstract
The urokinase-type plasminogen activator (uPA) system as a biomarkerand therapeutic target in human malignancies. . ???aop.label???. doi: 10.1517/14728222.2016.1113260Keywords
This publication has 160 references indexed in Scilit:
- Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancerMolecular Biology of the Cell, 2013
- The extracellular matrix: A dynamic niche in cancer progressionJournal of Cell Biology, 2012
- Reversibility of Epithelial-Mesenchymal Transition (EMT) Induced in Breast Cancer Cells by Activation of Urokinase Receptor-dependent Cell SignalingJournal of Biological Chemistry, 2009
- The interaction between urokinase receptor and vitronectin in cell adhesion and signallingEuropean Journal of Cell Biology, 2008
- Inhibition of Histone Deacetylase Activity Promotes Invasion of Human Cancer Cells through Activation of Urokinase Plasminogen ActivatorJournal of Biological Chemistry, 2007
- uPAR induces epithelial–mesenchymal transition in hypoxic breast cancer cellsJournal of Cell Biology, 2007
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Approaches for the sequence-specific knockdown of mRNANature Biotechnology, 2003
- Regulation of Rac1 activation by the low density lipoprotein receptor–related proteinJournal of Cell Biology, 2002
- Molecular Mechanisms Governing Tumor‐Necrosis‐Factor‐Mediated Regulation of Plasminogen‐Activator Inhibitor Type‐2 Gene ExpressionEuropean Journal of Biochemistry, 1996